Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478551 | 0.88 | CCR1 (0.39) | EGLN1KDM4ECCR1CCR8ALDH1A1 | |
| SCHEMBL6492314 | 0.81 | EGLN1 (0.59) | EGLN1ALDH1A1 | |
| SCHEMBL6492605 | 0.79 | CNR1 (0.36) | BRD4ADAMTS5ALDH1A1HPGD | |
| SCHEMBL2013978 | 0.76 | HTT (0.50) | PAX8COMTKDM4EBRD4CTSB | |
| SCHEMBL6480537 | 0.74 | FEN1 (0.60) | EGLN1ALDH1A1MPO | |
| SCHEMBL10561821 | 0.74 | KDM4E (0.55) | PAX8COMTKDM4EBRD4CTSB | |
| SCHEMBL7017317 | 0.73 | TAAR1 (0.45) | KDM4EADAMTS5HTTSLC6A2ALDH1A1 | |
| SCHEMBL3590445 | 0.73 | PAX8 (0.56) | EGLN1PAX8KDM4ECTSB | |
| SCHEMBL6479708 | 0.72 | ROCK1 (0.34) | ALDH1A1HPGDMPO | |
| SCHEMBL17970930 | 0.71 | EGLN1 (0.60) | EGLN1KDM4EADAMTS5KDM4AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | ZHUANG LINGHANG (US) | 2005-01-13 | — | — | US | claimed |
| EP-1333831-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002036734-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | claimed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140364389-A1 | Combination Therapy | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140364389-A1 | Combination Therapy | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8633219-B2 | Combination therapy | JAPAN TOBACCO INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633219-B2 | Combination therapy | JAPAN TOBACCO INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8232401-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232401-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-7531554-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7531554-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | ZHUANG LINGHANG (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1333831-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036734-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | EGLN1 2890/4885PAX8 4182/4885COMT 26/4885 |
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | POLI, CYP51A1, DUT | EGLN1 2187/4885PAX8 1786/4885COMT 1334/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | EGLN1 2764/4885PAX8 4127/4885COMT 19/4885 |
| US-20140364389-A1 | Combination Therapy | TYMP, TPMT, PNP | EGLN1 3113/4885PAX8 4414/4885COMT 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.